Evaluation of possible cause of weight change after Metformin and pioglitazone administration in patients with type 2 diabetes

Comparing the effects of metformin versus Pioglitazone administration on 2 hours plasma ghrelin level in patients with type 2 diabetes referred to diabetes clinic of Imam Khomeini Medical Complex during 2011

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT201102275917N1

Enrollment

Registered

2011-05-04

Start date

2011-03-06

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes mellitus. TypeII Diabetes mellitus

Interventions

Intervention 1: First group: Metformin 500 mg tablet orally bid for 3 month. Intervention 2: Second group: Pioglitazone 30 mg tablet orally daily for 3 month.

Treatment - Drugs

First group: Metformin 500 mg tablet orally bid for 3 month

Second group: Pioglitazone 30 mg tablet orally daily for 3 month

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion criteria: Patients with known type 2 diabetes mellitus more than 30 years Serum creatinine < 1.5 mg/dl in men and <1.4 mg/dl in women Exclusion criteria: Serious cardiovascular diseases Advanced renal or hepatic diseases Severe diabetes mellitus complications Poor compliance

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Plasma ghrelin. Timepoint: Before intervention, 3 month after intervention. Method of measurement: Serum ghrelin measurement after OGTT with 75 gram glucose.	—

Secondary

Measure	Time frame
Leptin. Timepoint: Before intervention,3month after intervention. Method of measurement: Plasma sample.;BMI. Timepoint: Before intervention,3month after intervention. Method of measurement: Weight/(height)2.;Fasting plasma insulin. Timepoint: Before intervention,3month after intervention. Method of measurement: Plasma sample.;ALT. Timepoint: Before intervention,3month after intervention. Method of measurement: Plasma sample.;Triglyceride. Timepoint: Before intervention,3month after intervention. Method of measurement: Plasma sample.;LDL. Timepoint: Before intervention,3month after intervention. Method of measurement: Plasma sample.;HDL. Timepoint: Before intervention,3month after intervention. Method of measurement: Plasma sample.;Weight. Timepoint: Before intervention,3 month after intervention. Method of measurement: Weight scale.;Fasting blood sugar. Timepoint: Before intervention,3month after intervention. Method of measurement: Plasma sample.;Blood pressure. Timepoint: Before intervention,3 month after intervention. Method of measurement: Sphygmomanometer.;HgbA1c. Timepoint: Before intervention,3month after intervention. Method of measurement: Plasma sample.	—

Measure

Time frame

Leptin. Timepoint: Before intervention,3month after intervention. Method of measurement: Plasma sample.;BMI. Timepoint: Before intervention,3month after intervention. Method of measurement: Weight/(height)2.;Fasting plasma insulin. Timepoint: Before intervention,3month after intervention. Method of measurement: Plasma sample.;ALT. Timepoint: Before intervention,3month after intervention. Method of measurement: Plasma sample.;Triglyceride. Timepoint: Before intervention,3month after intervention. Method of measurement: Plasma sample.;LDL. Timepoint: Before intervention,3month after intervention. Method of measurement: Plasma sample.;HDL. Timepoint: Before intervention,3month after intervention. Method of measurement: Plasma sample.;Weight. Timepoint: Before intervention,3 month after intervention. Method of measurement: Weight scale.;Fasting blood sugar. Timepoint: Before intervention,3month after intervention. Method of measurement: Plasma sample.;Blood pressure. Timepoint: Before intervention,3 month after intervention. Method of measurement: Sphygmomanometer.;HgbA1c. Timepoint: Before intervention,3month after intervention. Method of measurement: Plasma sample.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr.Hosein Moin Tavakkoli

Endocrine ward,Valiasr hospital,TUMS

htavakkoli@razi.tums.ac.ir+98 21 6119 2408

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Mar 9, 2026